Mesoblast Limited (ASX:MSB)
Australia · Delayed Price · Currency is AUD 2.390
-0.080 (-3.24%)
At close: Feb 5, 2026
Mesoblast Employees
Mesoblast had 81 employees as of June 30, 2025. The number of employees increased by 8 or 10.96% compared to the previous year.
Employees
81
Change (1Y)
8
Growth (1Y)
10.96%
Revenue / Employee
323.85K AUD
Profits / Employee
-1.92M AUD
Market Cap
3.08B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 81 | 8 | 10.96% |
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | 83 | -19 | -18.63% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mesoblast News
- 7 days ago - Ryoncil® Net Revenues Increase for the Quarter to US$30M - GlobeNewsWire
- 8 days ago - Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication - Benzinga
- 9 days ago - Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment - GlobeNewsWire
- 15 days ago - FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain - Benzinga
- 17 days ago - FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy - GlobeNewsWire
- 26 days ago - Mesoblast (MESO) Sees Revenue Surge and Secures $125M Loan - GuruFocus
- 26 days ago - Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales - Benzinga
- 27 days ago - Mesoblast Surges As Flagship Product Ryoncil Delivers Strong Quarterly Sales Growth - Nasdaq